lorazepam / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   33 Trials   33 Trials   2235 News 


«12...25262728293031323334353637»
  • ||||||||||  lorazepam / Generic mfg.
    Enrollment closed:  LORA-PITA IV General Investigation (clinicaltrials.gov) -  Aug 14, 2019   
    P=N/A,  N=200, Active, not recruiting, 
    No abstract available Not yet recruiting --> Active, not recruiting
  • ||||||||||  lorazepam / generics
    Journal:  Baclofen versus lorazepam for alcohol withdrawal. (Pubmed Central) -  Aug 9, 2019   
    Serious cardiac events may be more prevalent with either benzodiazepines or dexmedetomidine than propofol. No abstract available
  • ||||||||||  lorazepam / generics
    Effervescent Granules for the Treatment of Esophageal Food Bolus Obstruction (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_1648;    
    From January 2018 – August 2018, 21 patients met the inclusion criteria for the retrospective arm and were treated with the standard of care; from September 2018- April 2019, 33 patients met the inclusion criteria and were treated with effervescent granules for esophageal food bolus obstructions. 3 out of 21 patients from the retrospective arm and 20 out of 33 patients from the prospective arm had successful food bolus clearance without requiring an EGD (success rate = 14.3% vs. 60.6%; p = 0.002.) There was one complication of a Mallory-Weiss tear noted on endoscopy without clinical significance in a patient treated with effervescent granules.
  • ||||||||||  labetalol / Generic Mfg.
    A Rare Case of Heterozygous Hemochromatosis Presenting as Recurrent Pancreatitis (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_1454;    
    On that spectrum, pancreatitis is considered an extremely rare manifestation, never mention, the sole presenting manifestation of this disease. Clinicians should be cognizant of the variety of medical conditions that can cause pancreatitis and investigate them when clinically indicated.
  • ||||||||||  Recentin (cediranib) / AstraZeneca
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) -  Jul 18, 2019   
    P2,  N=70, Recruiting, 
    Thus, serum levels are not sufficient to guide management of tricyclic antidepressant intoxication. Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  allopregnanolone (LJPC-0712) / La Jolla Pharma
    Review, Journal:  An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action. (Pubmed Central) -  Jul 18, 2019   
    ...Etifoxine was first shown to be an effective anxiolytic in patients in clinical studies comparing it with clobazam, sulpiride, and placebo...Significantly less rebound anxiety was observed after abrupt cessation of etifoxine compared with lorazepam or alprazolam...Skin and subcutaneous disorders are the most frequently reported, but these generally resolve after drug cessation. Taken together, its dual mechanisms of action in anxiety and the positive data yielded by clinical trials support the use of etifoxine for treating the anxiety signs and symptoms of individuals with ADs.
  • ||||||||||  lorazepam / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care (clinicaltrials.gov) -  Jul 16, 2019   
    P2,  N=1, Terminated, 
    These interventions reduced utilization of critical care and mitigated hospital charges. N=120 --> 1 | Trial completion date: Dec 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Mar 2019; It was not feasible to enroll Emergency Department patients into this protocol
  • ||||||||||  risperidone / generics
    Clinical, Journal:  Treating an Adolescent with Long QT Syndrome for Bipolar Disorder: A Case Presentation. (Pubmed Central) -  Jul 7, 2019   
    This condition should be kept in mind especially in cases where familial risk factors are present and precautions need to be maintained upon required assessments. These cases need to be closely monitored due to risk factors related to both BD and LQTS, in a multidisciplinary fashion, involving both psychiatry and cardiology divisions.
  • ||||||||||  lorazepam / generics
    Journal:  Temporal glioblastoma presenting as catatonia. (Pubmed Central) -  Jun 22, 2019   
    ...He was diagnosed with catatonia and treated successfully with lorazepam...A postsurgical frontal syndrome with disinhibition and logorrhoea was present and gradually normalised over the course of several weeks. Catatonia can be the presenting symptom of a temporal brain tumour, and should therefore prompt the physician to a thorough medical investigation.
  • ||||||||||  lacosamide / generics
    Journal:  Absence status induced by lacosamide adjunctive therapy. (Pubmed Central) -  Jun 19, 2019   
    The absence status was successfully broken by lorazepam, and lacosamide was discontinued. The patient had no further confusional episodes at the most recent follow-up visit, four months after discharge.
  • ||||||||||  OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
    Trial completion, Enrollment change:  OSDI: Oral Sedation During Cervical Dilator Placement (clinicaltrials.gov) -  Jun 5, 2019   
    P4,  N=27, Completed, 
    Based on the results obtained further monitoring of venlafaxine, citalopram, and EDDP in coastal waters is recommended. Recruiting --> Completed | N=60 --> 27
  • ||||||||||  lorazepam / generics, haloperidol / generics
    Clinical, Journal:  Lorazepam Added to Haloperidol Effective for Agitated Delirium in End-of-Life Cancer Patients. (Pubmed Central) -  May 29, 2019   
    The application of the proposed methodology to real matrices resulted in average sample preparation time of around 2 min per sample, demonstrating that it is user-friendly, cost-effective and a rapid decision-making tool, whenever large number of samples are involved. No abstract available
  • ||||||||||  vigabatrin / generics, lorazepam / generics
    Clinical, Journal:  Catatonia Associated With a SCN2A-Related Disorder in a 4-Year-Old Child. (Pubmed Central) -  May 18, 2019   
    At the syndromic level, catatonia in young children appears responsive to high-dose lorazepam and is well monitored by using the Pediatric Catatonia Rating Scale. This case reveals the need for wide-ranging explorations in early-onset catatonia because specific targeted treatments might be available.
  • ||||||||||  Seizalam (midazolam intramuscular) / Pfizer
    Review, Journal:  Focal status epilepticus: a review of pharmacological treatment. (Pubmed Central) -  May 12, 2019   
    The available scientific evidence is insufficient to claim that pharmacological treatment of focal SE should be different from treatment for generalised SE. More studies with a greater number of patients are needed.
  • ||||||||||  Vivitrol (naltrexone extended-release injectable suspension) / Alkermes
    Journal:  Severe opioid withdrawal precipitated by Vivitrol®. (Pubmed Central) -  May 9, 2019   
    Recommended therapies include intravenous fluids, anti-emetics, clonidine, or benzodiazepines as well as therapy tailored to the organ system affected. To minimize risk of POW it is important for providers instituting XRNTX to adhere to the manufacturers warnings and clinic protocols including a naloxone challenge and ensure an adequate opioid free period prior to administration of XRNTX.
  • ||||||||||  lorazepam / Generic mfg., haloperidol / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer (clinicaltrials.gov) -  May 9, 2019   
    P2,  N=93, Active, not recruiting, 
    To minimize risk of POW it is important for providers instituting XRNTX to adhere to the manufacturers warnings and clinic protocols including a naloxone challenge and ensure an adequate opioid free period prior to administration of XRNTX. Trial completion date: Jan 2019 --> Jan 2021 | Trial primary completion date: Jan 2019 --> Jan 2021
  • ||||||||||  alprazolam / generics
    Journal:  Catatonia due to alprazolam withdrawal. (Pubmed Central) -  May 1, 2019   
    History from the patient's family revealed that 4 days prior to presentation, the patient had discontinued his prescribed dose of alprazolam 1 mg four times per day. The patient was diagnosed with catatonia due to benzodiazepine withdrawal and had gradual return to baseline with administration of lorazepam 1 mg intravenous three times per day.